沙库巴曲缬沙坦钠治疗老年慢性心力衰竭的效果

Curative effect of sacubitril/valsartan among elderly patients with chronic heart failure

目的探究沙库巴曲缬沙坦钠治疗老年慢性心力衰竭的临床效果。方法选取2018年1月至2019年12月在我院就诊的老年慢性心力衰竭患者86例,其中对照组42例,观察组44例;对照组给予患者包括β受体阻滞剂、血管紧张素转换酶抑制剂(ACEI)、利尿剂等规范抗心力衰竭治疗。观察组应用β受体阻滞剂、利尿剂基础上给予起始剂量沙库巴曲缬沙坦钠片25 mg,1天2次,2周后血压维持稳定情况下增加至50 mg,1天2次,治疗时间3个月。治疗3月后比较两组患者的临床疗效。结果观察组患者N末端B型利钠肽原(NT-proBNP)、左心室射血分数(LVEF)、常规C反应蛋白(CRP)、左室舒张末内径(LVEDD)改善程度显著高于对照组,差异有统计学意义(P<0.05)。观察组治疗有效率高于对照组,差异有统计学意义(P<0.05)。结论沙库巴曲缬沙坦钠具有抗动脉粥样硬化作用,用于治疗老年慢性心力衰竭效果显著。

Objective To observe the therapeutic effect of sacubitril valsartan in patients with chronic heart failure(CHF).Methods 86 patients with CHF were randomly divided into observation group(n=44)and control group(n=42).The control group was given routine anti-heart failure therapy.The observation group was treated with LCZ696 instead of ACEI,25 mg each time,twice per day.If the blood pressure was stable,the dose doubled 2 weeks later,50 mg each time,twice per day.All patients were treated continuously for 3 months.The clinical efficacy were compared between the two groups.Results The improvement of NT-proBNP,LVEF,routine CRP,LVEDD in the observation group were significantly higher than those in the control group.There were significant difference between the two groups(P<0.05).The effective rate of the observation group was higher than that of the control(P<0.05).Conclusion Sacubitril/valsartan has anti-atherosclerosis effect and can be used in the treatment of chronic heart failure in the elderly.